Drug Development

Listings
  • Anti-CEACAM5 (Labetuzumab)-CL3-SN-38 ADC

    Anti-CEACAM5 (Labetuzumab)-CL3-SN-38 ADC

    Drug Development Shirley (New York) November 23, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-CEACAM5 monoclonal antibody conjugated via a CL3 linker to a SN-38. The SN-38 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. The SN-38 is...

  • Anti-CEACAM5 (Labetuzumab)-CL1-SN-38 ADC

    Anti-CEACAM5 (Labetuzumab)-CL1-SN-38 ADC

    Drug Development Shirley (New York) November 23, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-CEACAM5 monoclonal antibody conjugated via a CL1 linker to a SN-38. The SN-38 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. The SN-38 is...

  • Anti-CEACAM5 (Labetuzumab)-CL2A-SN-38 ADC

    Anti-CEACAM5 (Labetuzumab)-CL2A-SN-38 ADC

    Drug Development Shirley (New York) November 23, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-CEACAM5 monoclonal antibody conjugated via a CL2A linker to a SN-38. The SN-38 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. The SN-38 i...

  • Anti-CEACAM5 (clone huMAb2-3)-SMCC-DM1 ADC

    Anti-CEACAM5 (clone huMAb2-3)-SMCC-DM1 ADC

    Drug Development Shirley (New York) November 23, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-CEACAM5 monoclonal antibody (clone huMAb2-3) conjugated via a SMCC linker to a DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis...

  • Anti-CEACAM5 (clone huMAb2-4)-SPDB-DM4 ADC

    Anti-CEACAM5 (clone huMAb2-4)-SPDB-DM4 ADC

    Drug Development Shirley (New York) November 23, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-CEACAM5 monoclonal antibody (clone huMAb2-4) conjugated via a SPDB linker to a DM4. The DM4 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis...

  • Anti-CEACAM5 (clone huMAb2-3)-sulfoSPDB-DM4 ADC

    Anti-CEACAM5 (clone huMAb2-3)-sulfoSPDB-DM4 ADC

    Drug Development Shirley (New York) November 23, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-CEACAM5 monoclonal antibody (clone huMAb2-3) conjugated via a sulfoSPDB linker to a DM4. The DM4 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocy...

  • Anti-CEACAM5 (clone huMAb2-3)-SPDB-DM4 ADC

    Anti-CEACAM5 (clone huMAb2-3)-SPDB-DM4 ADC

    Drug Development Shirley (New York) November 23, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-CEACAM5 monoclonal antibody (clone huMAb2-3) conjugated via a SPDB linker to a DM4. The DM4 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis...

  • Anti-CEACAM5 (clone huMAb2-1)-SPDB-DM4 ADC

    Anti-CEACAM5 (clone huMAb2-1)-SPDB-DM4 ADC

    Drug Development Shirley (New York) November 23, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-CEACAM5 monoclonal antibody (clone huMAb2-1) conjugated via a SPDB linker to a DM4. The DM4 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis...

  • Anti-CEACAM5 (clone huMAb2-2)-SPDB-DM4 ADC

    Anti-CEACAM5 (clone huMAb2-2)-SPDB-DM4 ADC

    Drug Development Shirley (New York) November 23, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-CEACAM5 monoclonal antibody (clone huMAb2-2) conjugated via a SPDB linker to a DM4. The DM4 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis...

  • Anti-CEACAM5 (clone chMAb1)-SPDB-DM4 ADC

    Anti-CEACAM5 (clone chMAb1)-SPDB-DM4 ADC

    Drug Development Shirley (New York) November 23, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-CEACAM5 monoclonal antibody (clone chMAb1) conjugated via a SPDB linker to a DM4. The DM4 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. ...

  • Anti-CEACAM5 (clone chMAb5)-SPDB-DM4 ADC

    Anti-CEACAM5 (clone chMAb5)-SPDB-DM4 ADC

    Drug Development Shirley (New York) November 23, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-CEACAM5 monoclonal antibody (clone chMAb5) conjugated via a SPDB linker to a DM4. The DM4 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. ...

  • Anti-CEACAM5 (clone chMAb4)-SPDB-DM4 ADC

    Anti-CEACAM5 (clone chMAb4)-SPDB-DM4 ADC

    Drug Development Shirley (New York) November 23, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-CEACAM5 monoclonal antibody (clone chMAb4) conjugated via a SPDB linker to a DM4. The DM4 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. ...